American Origin Unverified This profile is unclaimed and has not been independently reviewed. Claim & get verified

Oculis Holding AG (OCS)

$7.61 +0.26% NASDAQ: OCS · 15-min delayed

Public · NASDAQ: OCS
60 employees

Visit website Follow

$672.1MMarket cap

60Employees

OCSNASDAQ

2023IPO

About Oculis Holding AG

Oculis Holding AG is a biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The Company has locations in five countries: Switzerland, Iceland, France, U.S. and Hong Kong.

This profile is unclaimed. An authorized representative can claim it free to control the page and activate the embeddable Verified badge.

Company facts

Type: Public · NASDAQ: OCS
Employees: 60
IPO date: Mar 3, 2023
Industry: Pharmaceuticals
Website: Visit site

Incorporation record

Incorporated in: CH — outside the United States
Registered office: Zug, CH
Legal entity ID: 5067005370C2KK324336

Source: GLEIF, the global Legal Entity Identifier registry · checked Aug 8, 2026. A US headquarters does not always mean US incorporation.

Is Oculis Holding AG an American company? No. Oculis Holding AG is incorporated in Switzerland. It maintains US operations and its shares trade on NASDAQ — which is why it is often mistaken for a US company.

Registry IDs

Ticker: OCS Nasdaq
SEC CIK: 1953530
LEI: 5067005370C2KK324336
SIC: 2834 Pharmaceutical Preparations

Explore our data studies: the biggest company in every US state · all rankings & reports.

Embed this company’s badge

Show Oculis Holding AG’s American-company profile badge on a website — copy this HTML:

<a href="https://americancompanies.com/company/oculis-holding-ag/"><img src="https://americancompanies.com/badge/oculis-holding-ag.svg" alt="Oculis Holding AG — American company profile on americancompanies.com" width="220"></a>

Is this your company?

This profile is unclaimed — any authorized owner can claim it free, control the page, and activate the embeddable Verified badge for their own website.

Claim this profile — free

Track American companies

Create a free account to follow Oculis Holding AG and get an email when it moves sharply — real market data, 15-minute delayed.

Create free account

Reported figures

Financial summary

Market cap: $672.1M

NASDAQ: OCS

$7.61 +0.26%

15-minute delayed · data by Polygon.io

Past year · hover for prices

$6.83 $32.65

52-week range

Market cap: $672.1M
Shares outstanding: 88.3M
Open: —
Day range: –
Prev close: —
Volume: —
IPO date: Mar 3, 2023

Oculis Holding AG (OCS) Stock Price

Trading 77% below its 52-week high.

Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.

No reviews yet. Be the first to review Oculis Holding AG.

Write a review

Newsroom

News about Oculis Holding AG

Oculis to Host In-Person and Virtual R&D Day: Advancing a Differentiated Late-Stage Development Pipeline GlobeNewswire Inc. · 2026-11-09 · positive Oculis boðar til rannsóknar- og þróunardags (e. R&D Day) bæði í streymi og á staðnum: Framþróun þróunarlyfja með skýra sérstöðu á síðari stigum klínískrar þróunar GlobeNewswire Inc. · 2026-11-09 · positive Oculis Holding AG (OCS) Reports Q3 Loss, Lags Revenue Estimates Zacks Investment Research · 2026-11-03 · neutral Oculis Holding AG (OCS) Expected to Beat Earnings Estimates: Can the Stock Move Higher? Zacks Investment Research · 2026-11-02 · positive Oculis kynnir ný lífmerkisgögn (e. Biomarker Data) úr fasa 2 ACUITY-rannsókninni sem styðja enn frekar taugaverndandi möguleika Privosegtor við sjóntaugabólgu GlobeNewswire Inc. · 2026-10-22 · positive Oculis Reports New Phase 2 ACUITY Biomarker Data Further Supporting Privosegtor’s Neuroprotective Potential in Optic Neuritis GlobeNewswire Inc. · 2026-10-22 · positive

News & sentiment via Polygon.io

FAQ

Oculis Holding AG: frequently asked questions

Is Oculis Holding AG an American company?

No — Oculis Holding AG is not an American company. Oculis Holding AG is incorporated in Switzerland. It maintains US operations and its shares trade on NASDAQ — which is why it is often mistaken for a US company.

Where is Oculis Holding AG incorporated?

Oculis Holding AG is legally incorporated in Switzerland, according to its GLEIF legal-entity record.

Is Oculis Holding AG traded on a US stock exchange?

Yes — Oculis Holding AG trades under the ticker OCS on the NASDAQ. A US stock listing does not by itself make a company American — incorporation and ownership are what this page reports.

Is Oculis Holding AG publicly traded?

Yes — Oculis Holding AG is a publicly traded company. Its stock trades under the ticker symbol OCS on the NASDAQ.

What does Oculis Holding AG do?

Oculis Holding AG is an American Pharmaceuticals company in the Health & Beauty sector.

Explore